IL6 and COVID-19: A more recent study examining peripheral blood from patients with varying degrees of severity of COVID-19 also found that type I IFN responses were severely impaired in patients with severe or critical COVID-19, as indicated by low levels of IFN-I and ISG, despite increased production of tumor necrosis factor (TNF) and IL-6 and increased inflammatory responses controlled by NF-kB [54].